New insights into molecular mechanisms of sunitinib-associated side effects.
about
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaCombining radiotherapy with sunitinib: lessons (to be) learnedPET Metabolic Biomarkers for CancerBioGPS: The Music for the Chemo- and Bioinformatics Walzer.Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma.Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast CancerDual modulation of MCL-1 and mTOR determines the response to sunitinib.Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors.2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014).Polypharmacology: in silico methods of ligand design and development.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.Disseminated intravascular coagulation following administration of sunitinib.Guillain-Barré Syndrome following Treatment with Sunitinib Malate.Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib.Development and plasticity of meningeal lymphatic vessels.Targeting Myeloid-Derived Suppressor Cells in Cancer.[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
P2860
Q26784091-4BF07E2B-CF59-41A5-8927-CADF40FC86C4Q26800587-F2C437EB-5B61-4901-AC2A-56A8A874E617Q28074449-834FC51D-36E9-4A1D-9D86-B3512F9F35D8Q30391391-DC5AB3E4-1FCF-4348-89F5-C3C40DE76BCAQ33432282-17E954F4-4FFC-4A22-9E16-516BFCD815D0Q33691188-AC44914B-264A-49CD-BA36-C50B076FDA80Q37117596-FFC1E34D-5C5B-49B7-A0ED-3EF433E5B089Q37214094-353A5725-0D1B-408E-B798-4A3ED02899C7Q37544978-61EEA7AB-09DE-458B-8C88-B79DB40039F2Q37577963-E76B6CD6-BFC3-4735-AFDF-D3F94C7A834CQ38099390-10E3A974-5CB0-43F4-B460-407A7EE8D18EQ38631566-E6B3C009-EE27-4B4F-B9F0-8E542039B2A8Q38814901-21E15EEE-1599-417E-B27D-E90922CB4DA7Q38883187-8142C537-318F-40A6-801F-2CD9BF12AC89Q39048761-81D57C40-BEF7-4D25-AB0B-BAE3701131C8Q39172001-3D5A44C1-04DE-4F67-9C75-06E012A850E5Q40688319-9AD6F5ED-942E-4273-9555-4786BEF0E80DQ41465130-6FF134DD-7491-4175-B8EF-59E5B6467DA4Q42200105-4EF1682F-7578-4B2C-82B6-CD99EC8B1E40Q47344702-B9FC549C-7712-4564-BF58-51189B8DBAACQ47765346-B119CD2A-904B-4101-BBD0-A0DAFF5D4D81Q54195816-A9CD75C8-FF73-4E0D-9770-D61EC94DAA6DQ54196218-38E43957-8A6B-4A88-A1DD-AD39CA2B7CB9Q54344097-EB0A7D32-53BC-4549-B747-C630596A34FF
P2860
New insights into molecular mechanisms of sunitinib-associated side effects.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
New insights into molecular mechanisms of sunitinib-associated side effects.
@en
New insights into molecular mechanisms of sunitinib-associated side effects.
@nl
type
label
New insights into molecular mechanisms of sunitinib-associated side effects.
@en
New insights into molecular mechanisms of sunitinib-associated side effects.
@nl
prefLabel
New insights into molecular mechanisms of sunitinib-associated side effects.
@en
New insights into molecular mechanisms of sunitinib-associated side effects.
@nl
P2093
P1476
New insights into molecular mechanisms of sunitinib-associated side effects.
@en
P2093
Angélica Figueroa
Enrique Grande-Pulido
Guadalupe Aparicio-Gallego
Luis Antón-Aparicio
Manuel Valladares-Ayerbes
Moisés Blanco
Rosario García-Campelo
P304
P356
10.1158/1535-7163.MCT-10-1124
P577
2011-12-01T00:00:00Z